Who should we target for diabetes prevention and diabetes risk reduction?

Current Diabetes Reports

Volumn 12, Issue 2, 2012, Pages 147-156

  Blüher, Susann ^a   Markert, Jana ^a   Herget, Sabine ^a   Yates, Thomas ^b   Davis, Melanie ^b   Müller, Gabriele ^c   Waldow, Thomas ^c   Schwarz, Peter E H ^c,d  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Diabetes prevention; Diabetes risk factors; Risk score; Stepped risk strategy; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADOLESCENCE; ARTICLE; BLOOD ANALYSIS; BODY MASS; CHILDHOOD OBESITY; CLINICAL PRACTICE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEREDITY; HUMAN; IMMOBILIZATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTERVENTION STUDY; INTRAUTERINE GROWTH RETARDATION; LIFESTYLE MODIFICATION; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SCREENING TEST; SMALL FOR DATE INFANT; WAIST CIRCUMFERENCE;

DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; OBESITY; RISK REDUCTION BEHAVIOR; SEDENTARY LIFESTYLE; SENTINEL SURVEILLANCE; WAIST CIRCUMFERENCE;

EID: 84861097335     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0255-x     Document Type: Article

References (97)

1. Schwarz PE, Albright AL. Prevention of type 2 diabetes: the strategic approach for implementation. Horm Metab Res. 2011;43(13):907-10.
2. Schwarz PEH, et al. Diabetes prevention in practice, Vol. 1 In: Schwarz PEH, editor. Dresden: TUMAINI Institute for Prevention management; 2010. p. 268.
3. Lindstrom J, et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol. 2003;14(7 Suppl 2):S108-13. (Pubitemid 36750503)
4. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346 (6):393-403. (Pubitemid 34437694)
5. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-50. (Pubitemid 32378388)
6. Unwin N, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med. 2002;19(9):708-23. (Pubitemid 35013848)
7. Abdul-Ghani MA, et al. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006;29(7):1613-8. (Pubitemid 44127589)
8. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136(8):575-81. (Pubitemid 34407041)
9. Aekplakorn W, et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care. 2006;29(8):1872-7. (Pubitemid 44156645)
10. Wannamethee SG, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22):2644-50. (Pubitemid 41785063)
11. Kanaya AM, et al. Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule. Diabetes Care. 2005;28(2):404-8. (Pubitemid 40170947)
12. McNeely MJ, et al. Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care. 2003;26(3):758-63. (Pubitemid 36929340)
13. Gray LJ, et al. The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med. 2010;27(8):887-95.
14. Schwarz PE, et al. The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards Type 2 diabetes. J Clin Endocrinol Metab. 2009;94(3):920-6.
15. Schulze MB, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes: response to schwarz et Al. Diabetes Care. 2007;30(8):e88. (Pubitemid 47219448)
16. Glumer C, et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27(3):727-33. (Pubitemid 38280541)
17. Lindstrom J, Tuomilehto J. The Diabetes Risk Score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26 (3):725-31. (Pubitemid 36929335)
18. Schwarz PE, et al. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res. 2009;41(2):86-97.
19. American Diabetes Association. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32(7):1327-34.
20. National Institute for Health and Clinical Excellence. NICE public health guidance 35: Preventing type 2 diabetes: population and community-level interventions in high-risk groups and the general population, ed. London: National Institute for Health and Clinical Excellence; 2011.
21. Gillies CL, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336(7654):1180-5.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62-9.
23. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med. 2008;25(10):1151-6.
24. Paulweber B, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010;42 Suppl 1: S3-S36.
25. Gillies CL, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334 (7588):299.
26. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130-9. (Pubitemid 44115261)
27. Valensi P, et al. Pre-diabetes essential action: a European perspective. Diabetes Metab. 2005;31(6):606-20. (Pubitemid 43001181)
28. Schwarz PE, Lindstrom J. From evidence to practice-the IMAGE project-new standards in the prevention of type 2 diabetes. Diabetes Res Clin Pract. 2011;91(2):138-40.
29. Lindstrom J, et al. Take action to prevent diabetes-the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res. 2010;42 Suppl 1:S37-55.
30. Khunti K, et al. A comparison of screening strategies for Type 2 diabetes and impaired glucose tolerance in a UK community setting: a cost per case analysis. Diabetic Med. 2010;27(Suppl1): SD2-SD28.
31. Griffin SJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156-67.
32. Franciosi M, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28(5):1187-94. (Pubitemid 40616633)
33. Rathmann W, et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. Arch Intern Med. 2005;165(4):436-41. (Pubitemid 40280200)
34. Glumer C, Borch-Johnsen K, Colagiuri S. Can a screening programme for diabetes be applied to another population? Diabet Med. 2005;22(9):1234-8. (Pubitemid 41224185)
35. Mohan V, et al. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38). Diabetes Obes Metab. 2007;9(3):337-43. (Pubitemid 46502052)
36. Park PJ, et al. The performance of a risk score in predicting undiagnosed hyperglycemia. Diabetes Care. 2002;25(6):984-8. (Pubitemid 41110482)
37. Hippisley-Cox J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ. 2009;338:b880.
38. Taub NA, et al. Automated detection of high risk for impaired glucose regulation and type 2 diabetes mellitus, using primary care electronic data, in amulti-ethnic UK community setting. Diabetologia. 2009;52 Suppl 1:S325-6.
39. Abdul-Ghani MA, et al. Role of Glycated Hemoglobin in the Prediction of Future Risk of T2DM. J Clin Endocrinol Metab. 2011.
40. Abdul-Ghani M, DeFronzo RA. Fasting hyperglycemia impairs glucose - but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab. 2007;92(5):1778-84. (Pubitemid 46997188)
41. Abdul-Ghani MA, et al. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care. 2008;31(8):1650-5.
42. Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S194-8.
43. Brodsky J, et al. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care. 2011;34(2):292-5.
44. Pugh SK, et al. Abnormal 1 hour glucose challenge test followed by a normal 3 hour glucose tolerance test: does it identify adverse pregnancy outcome? J Miss State Med Assoc. 2011;51(1):3-6.
45. Skriver MV, et al. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish- Dutch Study of Intensive Treatment in People with Screen- Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia. 2011;53(11):2328-33.
46. Zhang X, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2011;33(7):1665-73.
47. Lorenzo C, et al. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2011;33(9):2104-9.
48. Hawley JA. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab Res Rev. 2004;20(5):383-93. (Pubitemid 39302963)
49. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol. 2005;99(3):1193-204. (Pubitemid 41214540)
50. Telford RD. Low physical activity and obesity: causes of chronic disease or simply predictors? Med Sci Sports Exerc. 2007;39 (8):1233-40. (Pubitemid 47344004)
51. Yates T, et al. Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care. 2009;32(8):1404-10.
52. Yates T, et al. The Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2 years? Diabet Med. 2011.
53. Laaksonen DE, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes. 2005;54 (1):158-65. (Pubitemid 40105108)
54. Sisson SB, Katzmarzyk PT. International prevalence of physical activity in youth and adults. Obes Rev. 2008;9(6):606-14.
55. Carlson SA, et al. Trend and prevalence estimates based on the 2008 Physical Activity Guidelines for Americans. Am J Prev Med. 2010;39(4):305-13.
56. NHS Information Centre. Health Survey for England: Physical activity and fitness. 2009. www.ic.nhs.uk/statistics-and-data-collections/health-and- lifestyles-related-surveys/health-survey-for-england/health-survey-for-england- 2008-physical-activity-and-fitness. 2009.
57. Troiano RP, et al. Physical activity in the United States measured by accelerometer. Med Sci Sports Exerc. 2008;40(1):181-8.
58. Craig CL, et al. International physical activity questionnaire: 12- country reliability and validity. Med Sci Sports Exerc. 2003;35 (8):1381-95. (Pubitemid 36936159)
59. Gill JM, et al. Sitting time and waist circumference are associated with glycemia in U.K. South Asians: data from 1,228 adults screened for the PODOSA trial. Diabetes Care. 2011;34(5):1214-8.
60. Whitlock G, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-96.
61. Thamer C, et al. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity (Silver Spring). 2007;15(2):531-8. (Pubitemid 46407335)
62. Salopuro TM, et al. Population-level effects of the national diabetes prevention programme (FIN-D2D) on the body weight, the waist circumference, and the prevalence of obesity. BMC Public Health. 2011;11:350.
63. Janiszewski PM, Janssen I, Ross R. Does waist circumference predict diabetes and cardiovascular disease beyond commonly evaluated cardiometabolic risk factors? Diabetes Care. 2007;30 (12):3105-9. (Pubitemid 350255257)
64. Zimmet P, et al. The metabolic syndrome in children and adolescents. Lancet. 2007;369(9579):2059-61. (Pubitemid 46935928)
65. Ingelsson E, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59 (5):1266-75.
66. Dupuis J, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105-16.
67. Loos RJ, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008;40(6):768-75. (Pubitemid 351748863)
68. Willer CJ, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008;40 (2):161-9. (Pubitemid 351171403)
69. Speliotes EK, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-48.
70. Prokopenko I, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77-81.
71. Lyssenko V, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82-8.
72. Chen WM, et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest. 2008;118(7):2620-8.
73. Saxena R, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42(2):142-8.
74. Zeggini E, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008.
75. Guan W, et al. Meta-analysis of 23 type 2 diabetes linkage studies from the International Type 2 Diabetes Linkage Analysis Consortium. Hum Hered. 2008;66(1):35-49. (Pubitemid 351342233)
76. Gaulton KJ, et al. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes. 2008;57(11):3136-44.
77. Soranzo N, et al. Common variants at 10 genomic loci influence hemoglobin A(C) levels via glycemic and nonglycemic pathways. Diabetes. 2011;59(12):3229-39.
78. Kathiresan S, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41(1):56-65.
79. Newton-Cheh C, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009.
80. Ehret GB, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478 (7367):103-9.
81. Fox ER, et al. Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet. 2011;20 (11):2273-84.
82. Stancakova A, et al. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes. 2009;58(9):2129-36.
83. Yogev Y, Visser GH. Obesity, gestational diabetes and pregnancy outcome. Semin Fetal Neonatal Med. 2009;14(2):77-84.
84. GillmanMW, et al. Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics. 2003;111(3):e221-6.
85. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35 (7):595-601.
86. Kanaka-Gantenbein C, Mastorakos G, Chrousos GP. Endocrinerelated causes and consequences of intrauterine growth retardation. Ann N Y Acad Sci. 2003;997:150-7. (Pubitemid 38491070)
87. Bush NC, et al. Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function. J Clin Endocrinol Metab. 2011;96(5):E803-9.
88. Orney A. Prenatal origin of obesity and their complications: gestational diabetes, maternal overweight and the paradoxical effects of fetal growth restriction and macrosimia. Reprod Toxicol. 2011;32:205-12.
89. Coupe B, et al. Nutritional programming affects hypothalamic organization and early response to leptin. Endocrinology. 2010;151 (2):702-13.
90. Park JH, et al. Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest. 2008;118(6):2316-24. (Pubitemid 351872348)
91. Han JC, Lawlor DA, Kimm SY. Childhood obesity. Lancet. 2010;375(9727):1737-48.
92. Bluher S, et al. Age-specific stabilization in obesity prevalence in German children: a cross-sectional study from 1999 to 2008. Int J Pediatr Obes. 2011;6(2-2):e199-206.
93. Wilmot EG, et al. Type 2 diabetes in younger adults: the emerging UK epidemic. Postgrad Med J. 2010;86(1022):711-8.
94. American Diabetes Association. Type 2 diabetes in children and adolescents. American Diabetes Association. Pediatrics. 2000;105 (3 Pt 1):671-80.
95. Hillier TA, Pedula KL. Complications in young adults with earlyonset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26(11):2999-3005. (Pubitemid 37345170)
96. Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007;357(23):2329-37. (Pubitemid 350223387)
97. Wilson AJ, et al. Lifestyle modification and metformin as long-term treatment options for obese adolescents: study protocol. BMC Public Health. 2009;9:434.